

Samuel L Aitken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6539325/publications.pdf>

Version: 2024-02-01

92
papers

2,747
citations

236833

25
h-index

206029

48
g-index

94
all docs

94
docs citations

94
times ranked

2905
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 29, 1-6.	0.9	1
2	Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac005.	0.4	10
3	Infectious Diseases Society of America Guidance on the Treatment of AmpC Î²-Lactamaseâ€‘Producing Enterobacterales, Carbapenem-Resistant <i>Acinetobacter baumannii</i> , and <i>Stenotrophomonas maltophilia</i> Infections. <i>Clinical Infectious Diseases</i> , 2022, 74, 2089-2114.	2.9	262
4	Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 848580.	1.8	2
5	Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i>). <i>Clinical Infectious Diseases</i> , 2022, 75, 187-212.	2.9	182
6	New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0261420.	1.4	19
7	Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With <i>Stenotrophomonas maltophilia</i> Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy. <i>Clinical Infectious Diseases</i> , 2021, 72, 1507-1513.	2.9	19
8	IS ₂₆ -mediated amplification of <i>bla</i> OXA-1 and <i>bla</i> CTX-M-15 with concurrent outer membrane porin disruption associated with <i>de novo</i> carbapenem resistance in a recurrent bacteraemia cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 385-395.	1.3	29
9	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i>). <i>Clinical Infectious Diseases</i> , 2021, 72, e169-e183.	2.9	292
10	<i>Clostridioides difficile</i> Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2021, 72, e460-e465.	2.9	9
11	Does Switching Norepinephrine to Phenylephrine in Septic Shock Complicated by Atrial Fibrillation With Rapid Ventricular Response Improve Time to Rate Control?. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 191-196.	1.3	5
12	Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. <i>Clinical Infectious Diseases</i> , 2021, 73, 1346-1354.	2.9	43
13	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i>). <i>Clinical Infectious Diseases</i> , 2021, 72, 1109-1116.	2.9	251
14	American Society for Transplantation and Cellular Therapy Series: #3â€‘Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 707-719.	0.6	45
15	The role of tazobactamâ€‘based combinations for the management of infections due to extendedâ€‘spectrum Î²-lactamaseâ€‘producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2021, 41, 864-880.	1.2	1
16	Extended Versus Short-Course Corticosteroid Taper Regimens in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Critically Ill Patients. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 257-263.	1.3	7
17	Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2038-2040.	1.4	8
18	An Overview of the Treatment of Less Common Nonâ€‘Lactoseâ€‘Fermenting Gramâ€‘Negative Bacteria. <i>Pharmacotherapy</i> , 2020, 40, 936-951.	1.2	26

#	ARTICLE	IF	CITATIONS
19	Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. <i>Leukemia and Lymphoma</i> , 2020, 61, 2488-2491.	0.6	21
20	Recommended Revisions to the National SEPâ€1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. <i>Pharmacotherapy</i> , 2020, 40, 368-371.	1.2	1
21	Outcomes of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant <i>Enterococcus faecalis</i> : Caution in Interpreting the Results. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	5
22	Activity of Cefiderocol and Comparators against Isolates from Cancer Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	38
23	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 346-350.	1.1	9
24	Optimization of intravenous immune globulin use at a comprehensive cancer center. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, S102-S106.	0.5	7
25	Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Treated With Ceftolozane/Tazobactam. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz416.	0.4	22
26	Antibiotic Consideration in Transplant Recipients. , 2019, , 855-901.		0
27	Treatment of Multidrug-Resistant Vancomycin-Resistant <i>Enterococcus faecium</i> Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	18
28	Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 303-313.	0.5	45
29	Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Preâ€ and Postâ€Hurricane Harvey. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz138.	0.4	13
30	Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1637-1641.	2.0	11
31	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019, 69, 903-904.	2.9	1
32	Antifungal Resistance: a Concerning Trend for the Present and Future. <i>Current Infectious Disease Reports</i> , 2019, 21, 47.	1.3	80
33	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019, 68, 1650-1657.	2.9	42
34	Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 68, 1641-1649.	2.9	71
35	Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-âˆ²-Lactamase-Producing <i>Escherichia coli</i> in Patients with Hematologic Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	23
36	Navigating manuscript assessment: The new practitionerâ€™s guide to primary literature peer review. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 94-100.	0.5	5

#	ARTICLE	IF	CITATIONS
37	Antimicrobial Stewardship in Cancer Patients: The Time is Now. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 772-775.	2.3	9
38	Clonal Emergence of Invasive Multidrug-Resistant <i>Staphylococcus epidermidis</i> Deconvoluted via a Combination of Whole-Genome Sequencing and Microbiome Analyses. <i>Clinical Infectious Diseases</i> , 2018, 67, 398-406.	2.9	27
39	Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2277-2283.	1.3	21
40	Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various Minimum Inhibitory Concentrations. <i>Journal of Pharmacy Practice</i> , 2018, 31, 34-39.	0.5	9
41	1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S421-S422.	0.4	2
42	1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI). <i>Open Forum Infectious Diseases</i> , 2018, 5, S47-S47.	0.4	0
43	1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S477-S477.	0.4	0
44	1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant. <i>Open Forum Infectious Diseases</i> , 2018, 5, S486-S486.	0.4	2
45	1055. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae Bacteremia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S315-S315.	0.4	0
46	Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 931-941.	1.3	17
47	Outcomes associated with <i>Clostridium difficile</i> infection in patients with chronic liver disease. <i>Epidemiology and Infection</i> , 2018, 146, 1101-1105.	1.0	18
48	Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant <i>Staphylococcus epidermidis</i> Bacteremia. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy167.	0.4	7
49	How common is subsequent central nervous system toxicity in asymptomatic patients with haematologic malignancy and supratherapeutic voriconazole serum levels?. <i>Clinical Microbiology and Infection</i> , 2017, 23, 387-390.	2.8	11
50	Significant publications on infectious diseases pharmacotherapy in 2015. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 238-252.	0.5	12
51	Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β -Lactams for Major Gram-Negative Bacterial Pathogens. <i>Clinical Infectious Diseases</i> , 2017, 65, 738-745.	2.9	56
52	Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	66
53	Solithromycin: A novel ketolide antibiotic. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 875-887.	0.5	24
54	Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2017, 65, 158-161.	2.9	123

#	ARTICLE	IF	CITATIONS
55	Evaluation of Fluoroquinolone Versus Other Antibiotic Prophylaxis Strategies in Adult Patients with AML Undergoing Induction Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S5-S6.	0.2	0
56	Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β -Lactamases?. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	5
57	Improving Antimicrobial Stewardship in Cancer Patients Through Implementation of Clinical Guidelines. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 333-346.	0.8	3
58	Daptomycin non-susceptible <i>Enterococcus faecium</i> in leukemia patients: Role of prior daptomycin exposure. <i>Journal of Infection</i> , 2017, 74, 243-247.	1.7	26
59	Ribotypes Matter, Significance of <i>Clostridium difficile</i> Ribotypes in Cancer Patients with Diarrhea. <i>Open Forum Infectious Diseases</i> , 2017, 4, S386-S387.	0.4	0
60	Risk Factors and Clinical Outcomes of Cancer Patients with <i>Clostridium difficile</i> Associated Diarrhea Co-infected with a Second Enteropathogen. <i>Open Forum Infectious Diseases</i> , 2017, 4, S362-S363.	0.4	0
61	Line of Service-Specific Performance and Antibiotic Prescribing Habits Following Introduction of a Two-Step Diagnostic Approach Using NAAT Followed by Enzyme Immunoassay in Cancer Patients with Suspected <i>Clostridium difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, S394-S394.	0.4	0
62	Empiric Linezolid Treatment Is Associated With Adverse Short-Term Outcomes in Patients With Linezolid-Resistant <i>Staphylococcus epidermidis</i> Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
63	Effectiveness and Safety of New Posaconazole Formulations in Patients With Hematologic Malignancy Receiving Antifungal Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
64	How Common is Subsequent Central Nervous System (CNS) Toxicity in Patients With Hematologic Malignancy (HM) and Supratherapeutic Voriconazole (VRC) Serum Levels?. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
65	Previous Daptomycin Exposure Predicts Daptomycin Non-Susceptible <i>Enterococcus faecium</i> Bloodstream Infections in Adult Leukemia Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
66	Development and Validation of a <i>Clostridium difficile</i> Health-related Quality-of-Life Questionnaire. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 631-637.	1.1	40
67	Aerosolized ribavirin: the most expensive drug for pneumonia. <i>Transplant Infectious Disease</i> , 2016, 18, 634-636.	0.7	52
68	Agricultural Applications for Antimicrobials. A Danger to Human Health: An Official Position Statement of the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2016, 36, 422-432.	1.2	15
69	Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infection in a Pediatric Leukemia Patient. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1040-1042.	1.1	32
70	Economic burden of primary compared with recurrent <i>Clostridium difficile</i> infection in hospitalized patients: a prospective cohort study. <i>Journal of Hospital Infection</i> , 2016, 93, 286-289.	1.4	59
71	Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria. <i>Current Infectious Disease Reports</i> , 2016, 18, 39.	1.3	11
72	Successful Treatment of Bloodstream Infection Due to Metallo- β -Lactamase-Producing <i>Stenotrophomonas maltophilia</i> in a Renal Transplant Patient. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5130-5134.	1.4	61

#	ARTICLE	IF	CITATIONS
73	Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study: Table 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3585-3587.	1.3	13
74	Regional variation in antibiotic prescribing among medicare part D enrollees, 2013. <i>BMC Infectious Diseases</i> , 2016, 16, 744.	1.3	31
75	High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo- β -lactamase Production in <i>Enterobacteriaceae</i> Bloodstream Infections at a Major Cancer Center: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 954-958.	2.9	55
76	Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 727-730.	1.3	10
77	In the Endemic Setting, <i>Clostridium difficile</i> Ribotype 027 Is Virulent But Not Hypervirulent. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1318-1323.	1.0	38
78	Regional and seasonal variation in <i>Clostridium difficile</i> infections among hospitalized patients in the United States, 2001-2010. <i>American Journal of Infection Control</i> , 2015, 43, 435-440.	1.1	27
79	Cefepime free minimum concentration to minimum inhibitory concentration (fC _{min} /MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 541-544.	1.1	58
80	Age-Stratified Treatment Response Rates in Hospitalized Patients with <i>Clostridium difficile</i> Infection Treated with Metronidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6113-6116.	1.4	11
81	Echinocandin Use in Hospitalized Patients: A Multi-institutional Study. <i>American Journal of the Medical Sciences</i> , 2015, 349, 316-320.	0.4	7
82	RhOD immune globulin products for prevention of alloimmunization during pregnancy. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 267-276.	0.5	7
83	Significant publications on infectious diseases pharmacotherapy in 2014. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1380-1392.	0.5	8
84	Response to "Effect of geographic region and seasonality on <i>Clostridium difficile</i> incidence and hospital mortality". <i>American Journal of Infection Control</i> , 2015, 43, 1379.	1.1	0
85	Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 4-8.	0.8	29
86	Healthcare Resource Utilization for Recurrent <i>Clostridium difficile</i> Infection in a Large University Hospital in Houston, Texas. <i>PLoS ONE</i> , 2014, 9, e102848.	1.1	21
87	Colonic Immunopathogenesis of <i>Clostridium difficile</i> Infections. <i>Vaccine Journal</i> , 2014, 21, 509-517.	3.2	25
88	Clinical Practice Patterns in Hospitalized Patients at Risk for Invasive Candidiasis. <i>Annals of Pharmacotherapy</i> , 2014, 48, 683-690.	0.9	36
89	Call for Antimicrobial Stewardship in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 2499.	2.6	22
90	Treatment of Extended-Spectrum Beta-Lactamase <i>Enterobacteriaceae</i> With Cefepime: The Dose Matters, Too. <i>Clinical Infectious Diseases</i> , 2013, 57, 915-916.	2.9	7

#	ARTICLE	IF	CITATIONS
91	Effect of Colistin on Phospholipid-Based Activated Partial Thromboplastin Time Clotting Assay Results in Patients Receiving Concomitant Heparin Therapy. <i>Pharmacotherapy</i> , 2011, 31, 277-279.	1.2	0
92	Potential for Linezolid-Related Blindness: A Review of Spontaneous Adverse Event Reports. <i>Pharmacotherapy</i> , 2011, 31, 585-590.	1.2	7